Press Releases
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 21, 2013Initial data from ongoing clinical study presented by MD Anderson Cancer Center and Trovagene at AACR-NCI-EORTC International Conferences highlights promise of urine-based, cell-free diagnostics
-
Oct 14, 2013Findings from studies investigating clinical validity of non-invasive cancer-mutation monitoring platform will be shared for first time at AACR-NCI-EORTC conference on October 21, 2013
-
Oct 1, 2013Cell-free DNA assay transferred to CLIA laboratory for patient testing
-
Sep 25, 2013
-
Sep 6, 2013Study to investigate Trovagene's non-invasive cancer monitoring technology using cell-free DNA from urine samples
-
Sep 4, 2013Rodman & Renshaw 15th Annual Global Healthcare Conference and Stifel Healthcare Conference 2013
-
Jul 29, 2013Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay
-
Jul 24, 2013Patent covers methods of detecting cell-free microRNA in urine and blood
-
Jul 22, 2013Trovagene develops ultra-sensitive cell-free DNA assay
-
Jun 27, 2013Presentation scheduled on June 27, 2013 at 9:20 a.m. ET in New York
-
Jun 3, 2013Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York
-
Mar 27, 2013New, non-invasive molecular diagnostic test is easy, fast, and accurate
-
Mar 12, 2013Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA
-
Feb 5, 2013Presentation scheduled on February 13, 2013 at 9:00 a.m. ET at the Waldorf Astoria in New York City
-
Jan 2, 2013Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes
-
Nov 18, 2012Renowned molecular geneticist strengthens Trovagene's scientific expertise
-
Nov 14, 2012COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
-
Aug 28, 2012Issuance of First US NPM1 Patent Triggers Milestone Payment
-
Aug 14, 2012COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE
-
Jul 2, 2012Study will compare detection of KRAS mutations in urine to their detection in biopsy samples
-
Jun 24, 2012
-
Apr 30, 2012Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics
-
Apr 30, 2012Trovagene Announces Validation Program for Trans-Renal K-RAS Mutation Detection in Pancreatic CancerCompany plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients
-
Apr 22, 2012- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -